| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | Ly6g |
| Uniprot No | P35461 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 4-96aa |
| 氨基酸序列 | LECYNCIGVPPETSCNTTTCPFSDGFCVALEIEVIVDSHRSKVKSNLCLP ICPTTLDNTEITGNAVNVKTYCCKEDLCNAAVPTGGSSWTMAG |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ly6g重组蛋白的3篇代表性文献摘要(基于公开研究内容概括，非真实文献)：
1. **文献名称**：*Ly6G重组蛋白在小鼠中性粒细胞功能研究中的应用*
**作者**：Smith A, et al.
**摘要**：该研究通过大肠杆菌表达系统成功纯化重组Ly6G蛋白，验证其与中性粒细胞表面受体的特异性结合能力，并证明其在体外抑制中性粒细胞迁移的功能，为炎症调控提供了潜在工具。
2. **文献名称**：*重组Ly6G蛋白的结构解析及其免疫调节机制*
**作者**：Zhang L, et al.
**摘要**：通过X射线晶体学解析了Ly6G重组蛋白的三维结构，发现其特有的糖基化位点对Toll样受体信号通路具有调控作用，揭示了其在脓毒症模型中的抗炎效果。
3. **文献名称**：*靶向Ly6G的融合蛋白在肿瘤微环境中的治疗潜力*
**作者**：Brown K, et al.
**摘要**：构建了Ly6G重组蛋白与免疫检查点抑制剂的融合分子，实验显示其可特异性靶向肿瘤相关中性粒细胞，显著增强抗PD-1疗法在黑色素瘤模型中的疗效。
(注：以上为示例性内容，实际文献需通过PubMed或Google Scholar等平台检索。)
Ly6G (Lymphocyte Antigen 6 Complex, Locus G) is a glycosylphosphatidylinositol (GPI)-anchored protein predominantly expressed on neutrophils and subsets of myeloid cells. It belongs to the Ly6/uPAR superfamily, characterized by conserved LU domain structures involved in cell adhesion, migration, and immune regulation. Ly6G forms a heterodimeric complex with Ly6C, collectively known as Gr-1 in mice, and serves as a key marker for identifying and isolating neutrophils in both murine and human studies.
Recombinant Ly6G proteins are engineered versions produced in expression systems (e.g., mammalian, insect, or bacterial cells) to study its biological functions without requiring native cell sources. These proteins typically retain critical structural features, including the conserved LU domain responsible for ligand interactions. Researchers utilize Ly6G recombinant proteins to investigate neutrophil activation, trafficking, and interactions with endothelial cells or pathogens during inflammation. They are also employed in antibody development, competitive binding assays, and mechanistic studies of neutrophil-mediated immune responses in conditions like sepsis, autoimmune diseases, and cancer.
In therapeutic contexts, Ly6G-targeting strategies using recombinant proteins or antibodies have been explored to modulate neutrophil activity. For example, anti-Ly6G antibodies are used experimentally to deplete neutrophils in murine models, helping dissect their roles in disease progression. However, species-specific differences exist: murine Ly6G shares ~60% amino acid homology with human LY6G, necessitating careful model selection.
The production of Ly6G recombinant proteins often includes tags (e.g., His, Fc) for purification and detection. Quality validation involves SDS-PAGE, Western blotting, and functional assays confirming binding to known partners like CXCR2 or pathogen-associated molecules. Ongoing research continues to clarify Ly6G’s signaling mechanisms and its potential as a diagnostic or therapeutic target in neutrophilic inflammation.
×
